The Asia Pacific Inflammatory Bowel Disease Treatment Market would witness market growth of 9.9% CAGR during the forecast period (2021-2027).
Inflammatory bowel disease refers to the medical indication that is responsible to cause chronic inflammation in the gastrointestinal tract. This disease includes Crohn’s disease and Ulcerative colitis. The ulcerative colitis majorly attacks the large intestine and anus. Moreover, it also causes inflammation of sores in the inner lining of the rectum and colon. On the other hand, Crohn’s disease can attack any part of the gastrointestinal tract and any layer of gastrointestinal walls. The prevalence of ulcerative colitis is witnessed more in comparison to Crohn’s disease. Further, the effect of inflammatory bowel disease is witnessed equally on women as well as men and the incidence & prevalence rates are higher in well-established nations as compared to under-developed nations or emerging nations.
The combination of various factors responsible to cause inflammatory bowel disease are genetic factors, autoimmune disorders, and unhealthy lifestyles like sedentary lifestyle, lack of exercise, and smoking. Though, persistent diarrhea, occasional rectal bleeding, and severe abdominal pain & cramps are some of the major symptoms of inflammatory bowel disease. Inflammatory bowel disease is a lifelong disease that requires continuous treatment and management. The medications majorly used to slow the progress of inflammatory bowel disease are immunomodulators, aminosalicylates, corticosteroids, and biologic drugs like TNF inhibitors. Sometimes, antibiotic drugs are also recommended to control the progress of the disease.
The inflammatory bowel disease treatment market is displaying a significant growth in Asia-Pacific. The factors contributing to the growth of the market are growing access to healthcare, increasing per capita medical expenditure, and a rise in the number of patients with inflammatory bowel disease. Additionally, the prevalence of inflammatory bowel disease is higher in several nations in this region like Australia, India, New Zealand, and China.
Moreover, nations in this region are rapidly developing due to which, the eating habits of people residing in such nations are also changing. The changing eating habits have given rise to various health problems and diseases. Moreover, China is known to be the hub of various industries. The advent of new technologies in this region has made people lazy, which has resulted in obesity and thus, has given rise to inflammatory bowel disease. Hence, these factors are likely to escalate the growth of the regional inflammatory bowel disease treatment market in the upcoming period.
The China market dominated the Asia Pacific Oral Market by Country 2020, and would continue to be a dominant market till 2027; thereby, achieving a market value of $530.5 million by 2027. The Japan market showcasing a CAGR of 11.3% during (2021 - 2027). Additionally, The India market is poised to grow at a CAGR of 13% during (2021 - 2027).
Based on Type, the market is segmented into Crohn's Disease and Ulcerative Colitis. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy and Online Pharmacy. Based on Route of Administration, the market is segmented into Injectable and Oral. Based on Drug Class, the market is segmented into TNF inhibitors, Anti-integrin, IL inhibitors, Corticosteroids, JAK inhibitors, Aminosalicylates and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
Free Valuable Insights: The Worldwide Inflammatory Bowel Disease Treatment Market is Projected to reach USD 29.2 Billion by 2027, at a CAGR of 8.1%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Allergan PLC (AbbVie), Johnson & Johnson, Merck Group, Amgen, Inc., Eli Lilly and Company, Biogen, Inc., Pfizer, Inc., Novartis AG, Takeda Pharmaceutical Company Limited, and UCB S.A.
Scope of the Study
Market Segments Covered in the Report:
By Type
- Crohn's Disease and
- Ulcerative Colitis
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
By Route of Administration
By Drug Class
- TNF inhibitors
- Anti-integrin
- IL inhibitors
- Corticosteroids
- JAK inhibitors
- Aminosalicylates
- Others
By Country
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- Allergan PLC (AbbVie)
- Johnson & Johnson
- Merck Group
- Amgen, Inc.
- Eli Lilly and Company
- Biogen, Inc.
- Pfizer, Inc.
- Novartis AG
- Takeda Pharmaceutical Company Limited
- UCB S.A.
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Asia Pacific Inflammatory Bowel Disease Treatment Market, by Type
1.4.2 Asia Pacific Inflammatory Bowel Disease Treatment Market, by Distribution Channel
1.4.3 Asia Pacific Inflammatory Bowel Disease Treatment Market, by Route of Administration
1.4.4 Asia Pacific Inflammatory Bowel Disease Treatment Market, by Drug Class
1.4.5 Asia Pacific Inflammatory Bowel Disease Treatment Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.2 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Acquisition and Mergers
3.2.4 Geographical Expansions
3.2.5 Approvals and Trials
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2017-2021)
3.3.2 Key Strategic Move: (Approvals and Trials : 2017, Aug – 2021, Sep) Leading Players
Chapter 4. Asia Pacific Inflammatory Bowel Disease Treatment Market by Type
4.1 Asia Pacific Crohn's Disease Market by Country
4.2 Asia Pacific Ulcerative Colitis Market by Country
Chapter 5. Asia Pacific Inflammatory Bowel Disease Treatment Market by Distribution Channel
5.1 Asia Pacific Hospital Pharmacy Market by Country
5.2 Asia Pacific Retail Pharmacy Market by Country
5.3 Asia Pacific Online Pharmacy Market by Country
Chapter 6. Asia Pacific Inflammatory Bowel Disease Treatment Market by Route of Administration
6.1 Asia Pacific Injectable Market by Country
6.2 Asia Pacific Oral Market by Country
Chapter 7. Asia Pacific Inflammatory Bowel Disease Treatment Market by Drug Class
7.1 Asia Pacific TNF inhibitors Market by Country
7.2 Asia Pacific Anti-integrin Market by Country
7.3 Asia Pacific IL inhibitors Market by Country
7.4 Asia Pacific Corticosteroids Market by Country
7.5 Asia Pacific JAK inhibitors Market by Country
7.6 Asia Pacific Aminosalicylates Market by Country
7.7 Asia Pacific Others Market by Country
Chapter 8. Asia Pacific Inflammatory Bowel Disease Treatment Market by Country
8.1 China Inflammatory Bowel Disease Treatment Market
8.1.1 China Inflammatory Bowel Disease Treatment Market by Type
8.1.2 China Inflammatory Bowel Disease Treatment Market by Distribution Channel
8.1.3 China Inflammatory Bowel Disease Treatment Market by Route of Administration
8.1.4 China Inflammatory Bowel Disease Treatment Market by Drug Class
8.2 Japan Inflammatory Bowel Disease Treatment Market
8.2.1 Japan Inflammatory Bowel Disease Treatment Market by Type
8.2.2 Japan Inflammatory Bowel Disease Treatment Market by Distribution Channel
8.2.3 Japan Inflammatory Bowel Disease Treatment Market by Route of Administration
8.2.4 Japan Inflammatory Bowel Disease Treatment Market by Drug Class
8.3 India Inflammatory Bowel Disease Treatment Market
8.3.1 India Inflammatory Bowel Disease Treatment Market by Type
8.3.2 India Inflammatory Bowel Disease Treatment Market by Distribution Channel
8.3.3 India Inflammatory Bowel Disease Treatment Market by Route of Administration
8.3.4 India Inflammatory Bowel Disease Treatment Market by Drug Class
8.4 South Korea Inflammatory Bowel Disease Treatment Market
8.4.1 South Korea Inflammatory Bowel Disease Treatment Market by Type
8.4.2 South Korea Inflammatory Bowel Disease Treatment Market by Distribution Channel
8.4.3 South Korea Inflammatory Bowel Disease Treatment Market by Route of Administration
8.4.4 South Korea Inflammatory Bowel Disease Treatment Market by Drug Class
8.5 Singapore Inflammatory Bowel Disease Treatment Market
8.5.1 Singapore Inflammatory Bowel Disease Treatment Market by Type
8.5.2 Singapore Inflammatory Bowel Disease Treatment Market by Distribution Channel
8.5.3 Singapore Inflammatory Bowel Disease Treatment Market by Route of Administration
8.5.4 Singapore Inflammatory Bowel Disease Treatment Market by Drug Class
8.6 Malaysia Inflammatory Bowel Disease Treatment Market
8.6.1 Malaysia Inflammatory Bowel Disease Treatment Market by Type
8.6.2 Malaysia Inflammatory Bowel Disease Treatment Market by Distribution Channel
8.6.3 Malaysia Inflammatory Bowel Disease Treatment Market by Route of Administration
8.6.4 Malaysia Inflammatory Bowel Disease Treatment Market by Drug Class
8.7 Rest of Asia Pacific Inflammatory Bowel Disease Treatment Market
8.7.1 Rest of Asia Pacific Inflammatory Bowel Disease Treatment Market by Type
8.7.2 Rest of Asia Pacific Inflammatory Bowel Disease Treatment Market by Distribution Channel
8.7.3 Rest of Asia Pacific Inflammatory Bowel Disease Treatment Market by Route of Administration
8.7.4 Rest of Asia Pacific Inflammatory Bowel Disease Treatment Market by Drug Class
Chapter 9. Company Profiles
9.1 Allergan PLC (AbbVie)
9.1.1 Company Overview
9.1.2 Financial Analysis
9.1.3 Regional Analysis
9.1.4 Research & Development Expense
9.1.5 Recent strategies and developments:
9.1.5.1 Approvals and Trials:
9.2 Johnson & Johnson
9.2.1 Company Overview
9.2.2 Financial Analysis
9.2.3 Segmental &Regional Analysis
9.2.4 Research & Development Expenses
9.2.5 Recent strategies and developments:
9.2.5.1 Partnerships, Collaborations, and Agreements:
9.2.5.2 Approvals and Trials:
9.3 Merck Group
9.3.1 Company Overview
9.3.2 Financial Analysis
9.3.3 Segmental and Regional Analysis
9.3.4 Research & Development Expense
9.3.5 Recent strategies and developments:
9.3.5.1 Partnerships, Collaborations, and Agreements:
9.3.5.2 Acquisitions and Mergers:
9.3.5.3 Product Launches and Product Expansions:
9.4 Amgen, Inc.
9.4.1 Company Overview
9.4.2 Financial Analysis
9.4.3 Regional Analysis
9.4.4 Research & Development Expenses
9.4.5 Recent strategies and developments:
9.4.5.1 Partnerships, Collaborations, and Agreements:
9.4.5.2 Acquisitions and Mergers:
9.4.5.3 Geographical Expansions:
9.4.5.4 Approvals and Trials:
9.5 Eli Lilly and Company
9.5.1 Company Overview
9.5.2 Financial Analysis
9.5.3 Regional Analysis
9.5.4 Research & Development Expense
9.6 Biogen, Inc.
9.6.1 Company Overview
9.6.2 Financial Analysis
9.6.3 Regional Analysis
9.6.4 Research & Development Expense
9.6.5 Recent strategies and developments:
9.6.5.1 Partnerships, Collaborations, and Agreements:
9.6.5.2 Product Launches and Product Expansions:
9.6.5.3 Approvals and Trials:
9.7 Pfizer, Inc.
9.7.1 Company Overview
9.7.2 Financial Analysis
9.7.3 Regional Analysis
9.7.4 Research & Development Expense
9.7.5 Recent strategies and developments:
9.7.5.1 Acquisitions and Mergers:
9.7.5.2 Approvals and Trials:
9.8 Novartis AG
9.8.1 Company Overview
9.8.2 Financial Analysis
9.8.3 Segmental and Regional Analysis
9.8.4 Research & Development Expense
9.8.5 Recent strategies and developments:
9.8.5.1 Partnerships, Collaborations, and Agreements:
9.8.5.2 Acquisitions and Mergers:
9.8.5.3 Approvals and Trials:
9.9 Takeda Pharmaceutical Company Limited
9.9.1 Company Overview
9.9.2 Financial Analysis
9.9.3 Regional Analysis
9.9.4 Research & Development Expense
9.9.5 Recent strategies and developments:
9.9.5.1 Partnerships, Collaborations, and Agreements:
9.9.5.2 Acquisitions and Mergers:
9.9.5.3 Product Launches and Product Expansions:
9.9.5.4 Approvals and Trials:
9.10. UCB S.A.
9.10.1 Company Overview
9.10.2 Financial Analysis
9.10.3 Regional Analysis
9.10.4 Research & Development Expense
9.10.5 Recent strategies and developments:
9.10.5.1 Partnerships, Collaborations, and Agreements:
9.10.5.2 Approvals and Trials:
TABLE 1 Asia Pacific Inflammatory Bowel Disease Treatment Market, 2017 - 2020, USD Million
TABLE 2 Asia Pacific Inflammatory Bowel Disease Treatment Market, 2021 - 2027, USD Million
TABLE 3 Partnerships, Collaborations and Agreements– Inflammatory Bowel Disease Treatment Market
TABLE 4 Product Launches And Product Expansions– Inflammatory Bowel Disease Treatment Market
TABLE 5 Acquisition and Mergers– Inflammatory Bowel Disease Treatment Market
TABLE 6 Geographical Expansions– Inflammatory Bowel Disease Treatment Market
TABLE 7 Approvals and TRials– Inflammatory Bowel Disease Treatment Market
TABLE 8 Asia Pacific Inflammatory Bowel Disease Treatment Market by Type, 2017 - 2020, USD Million
TABLE 9 Asia Pacific Inflammatory Bowel Disease Treatment Market by Type, 2021 - 2027, USD Million
TABLE 10 Asia Pacific Crohn's Disease Market by Country, 2017 - 2020, USD Million
TABLE 11 Asia Pacific Crohn's Disease Market by Country, 2021 - 2027, USD Million
TABLE 12 Asia Pacific Ulcerative Colitis Market by Country, 2017 - 2020, USD Million
TABLE 13 Asia Pacific Ulcerative Colitis Market by Country, 2021 - 2027, USD Million
TABLE 14 Asia Pacific Inflammatory Bowel Disease Treatment Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 15 Asia Pacific Inflammatory Bowel Disease Treatment Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 16 Asia Pacific Hospital Pharmacy Market by Country, 2017 - 2020, USD Million
TABLE 17 Asia Pacific Hospital Pharmacy Market by Country, 2021 - 2027, USD Million
TABLE 18 Asia Pacific Retail Pharmacy Market by Country, 2017 - 2020, USD Million
TABLE 19 Asia Pacific Retail Pharmacy Market by Country, 2021 - 2027, USD Million
TABLE 20 Asia Pacific Online Pharmacy Market by Country, 2017 - 2020, USD Million
TABLE 21 Asia Pacific Online Pharmacy Market by Country, 2021 - 2027, USD Million
TABLE 22 Asia Pacific Inflammatory Bowel Disease Treatment Market by Route of Administration, 2017 - 2020, USD Million
TABLE 23 Asia Pacific Inflammatory Bowel Disease Treatment Market by Route of Administration, 2021 - 2027, USD Million
TABLE 24 Asia Pacific Injectable Market by Country, 2017 - 2020, USD Million
TABLE 25 Asia Pacific Injectable Market by Country, 2021 - 2027, USD Million
TABLE 26 Asia Pacific Oral Market by Country, 2017 - 2020, USD Million
TABLE 27 Asia Pacific Oral Market by Country, 2021 - 2027, USD Million
TABLE 28 Asia Pacific Inflammatory Bowel Disease Treatment Market by Drug Class, 2017 - 2020, USD Million
TABLE 29 Asia Pacific Inflammatory Bowel Disease Treatment Market by Drug Class, 2021 - 2027, USD Million
TABLE 30 Asia Pacific TNF inhibitors Market by Country, 2017 - 2020, USD Million
TABLE 31 Asia Pacific TNF inhibitors Market by Country, 2021 - 2027, USD Million
TABLE 32 Asia Pacific Anti-integrin Market by Country, 2017 - 2020, USD Million
TABLE 33 Asia Pacific Anti-integrin Market by Country, 2021 - 2027, USD Million
TABLE 34 Asia Pacific IL inhibitors Market by Country, 2017 - 2020, USD Million
TABLE 35 Asia Pacific IL inhibitors Market by Country, 2021 - 2027, USD Million
TABLE 36 Asia Pacific Corticosteroids Market by Country, 2017 - 2020, USD Million
TABLE 37 Asia Pacific Corticosteroids Market by Country, 2021 - 2027, USD Million
TABLE 38 Asia Pacific JAK inhibitors Market by Country, 2017 - 2020, USD Million
TABLE 39 Asia Pacific JAK inhibitors Market by Country, 2021 - 2027, USD Million
TABLE 40 Asia Pacific Aminosalicylates Market by Country, 2017 - 2020, USD Million
TABLE 41 Asia Pacific Aminosalicylates Market by Country, 2021 - 2027, USD Million
TABLE 42 Asia Pacific Others Market by Country, 2017 - 2020, USD Million
TABLE 43 Asia Pacific Others Market by Country, 2021 - 2027, USD Million
TABLE 44 Asia Pacific Inflammatory Bowel Disease Treatment Market by Country, 2017 - 2020, USD Million
TABLE 45 Asia Pacific Inflammatory Bowel Disease Treatment Market by Country, 2021 - 2027, USD Million
TABLE 46 China Inflammatory Bowel Disease Treatment Market, 2017 - 2020, USD Million
TABLE 47 China Inflammatory Bowel Disease Treatment Market, 2021 - 2027, USD Million
TABLE 48 China Inflammatory Bowel Disease Treatment Market by Type, 2017 - 2020, USD Million
TABLE 49 China Inflammatory Bowel Disease Treatment Market by Type, 2021 - 2027, USD Million
TABLE 50 China Inflammatory Bowel Disease Treatment Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 51 China Inflammatory Bowel Disease Treatment Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 52 China Inflammatory Bowel Disease Treatment Market by Route of Administration, 2017 - 2020, USD Million
TABLE 53 China Inflammatory Bowel Disease Treatment Market by Route of Administration, 2021 - 2027, USD Million
TABLE 54 China Inflammatory Bowel Disease Treatment Market by Drug Class, 2017 - 2020, USD Million
TABLE 55 China Inflammatory Bowel Disease Treatment Market by Drug Class, 2021 - 2027, USD Million
TABLE 56 Japan Inflammatory Bowel Disease Treatment Market, 2017 - 2020, USD Million
TABLE 57 Japan Inflammatory Bowel Disease Treatment Market, 2021 - 2027, USD Million
TABLE 58 Japan Inflammatory Bowel Disease Treatment Market by Type, 2017 - 2020, USD Million
TABLE 59 Japan Inflammatory Bowel Disease Treatment Market by Type, 2021 - 2027, USD Million
TABLE 60 Japan Inflammatory Bowel Disease Treatment Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 61 Japan Inflammatory Bowel Disease Treatment Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 62 Japan Inflammatory Bowel Disease Treatment Market by Route of Administration, 2017 - 2020, USD Million
TABLE 63 Japan Inflammatory Bowel Disease Treatment Market by Route of Administration, 2021 - 2027, USD Million
TABLE 64 Japan Inflammatory Bowel Disease Treatment Market by Drug Class, 2017 - 2020, USD Million
TABLE 65 Japan Inflammatory Bowel Disease Treatment Market by Drug Class, 2021 - 2027, USD Million
TABLE 66 India Inflammatory Bowel Disease Treatment Market, 2017 - 2020, USD Million
TABLE 67 India Inflammatory Bowel Disease Treatment Market, 2021 - 2027, USD Million
TABLE 68 India Inflammatory Bowel Disease Treatment Market by Type, 2017 - 2020, USD Million
TABLE 69 India Inflammatory Bowel Disease Treatment Market by Type, 2021 - 2027, USD Million
TABLE 70 India Inflammatory Bowel Disease Treatment Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 71 India Inflammatory Bowel Disease Treatment Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 72 India Inflammatory Bowel Disease Treatment Market by Route of Administration, 2017 - 2020, USD Million
TABLE 73 India Inflammatory Bowel Disease Treatment Market by Route of Administration, 2021 - 2027, USD Million
TABLE 74 India Inflammatory Bowel Disease Treatment Market by Drug Class, 2017 - 2020, USD Million
TABLE 75 India Inflammatory Bowel Disease Treatment Market by Drug Class, 2021 - 2027, USD Million
TABLE 76 South Korea Inflammatory Bowel Disease Treatment Market, 2017 - 2020, USD Million
TABLE 77 South Korea Inflammatory Bowel Disease Treatment Market, 2021 - 2027, USD Million
TABLE 78 South Korea Inflammatory Bowel Disease Treatment Market by Type, 2017 - 2020, USD Million
TABLE 79 South Korea Inflammatory Bowel Disease Treatment Market by Type, 2021 - 2027, USD Million
TABLE 80 South Korea Inflammatory Bowel Disease Treatment Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 81 South Korea Inflammatory Bowel Disease Treatment Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 82 South Korea Inflammatory Bowel Disease Treatment Market by Route of Administration, 2017 - 2020, USD Million
TABLE 83 South Korea Inflammatory Bowel Disease Treatment Market by Route of Administration, 2021 - 2027, USD Million
TABLE 84 South Korea Inflammatory Bowel Disease Treatment Market by Drug Class, 2017 - 2020, USD Million
TABLE 85 South Korea Inflammatory Bowel Disease Treatment Market by Drug Class, 2021 - 2027, USD Million
TABLE 86 Singapore Inflammatory Bowel Disease Treatment Market, 2017 - 2020, USD Million
TABLE 87 Singapore Inflammatory Bowel Disease Treatment Market, 2021 - 2027, USD Million
TABLE 88 Singapore Inflammatory Bowel Disease Treatment Market by Type, 2017 - 2020, USD Million
TABLE 89 Singapore Inflammatory Bowel Disease Treatment Market by Type, 2021 - 2027, USD Million
TABLE 90 Singapore Inflammatory Bowel Disease Treatment Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 91 Singapore Inflammatory Bowel Disease Treatment Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 92 Singapore Inflammatory Bowel Disease Treatment Market by Route of Administration, 2017 - 2020, USD Million
TABLE 93 Singapore Inflammatory Bowel Disease Treatment Market by Route of Administration, 2021 - 2027, USD Million
TABLE 94 Singapore Inflammatory Bowel Disease Treatment Market by Drug Class, 2017 - 2020, USD Million
TABLE 95 Singapore Inflammatory Bowel Disease Treatment Market by Drug Class, 2021 - 2027, USD Million
TABLE 96 Malaysia Inflammatory Bowel Disease Treatment Market, 2017 - 2020, USD Million
TABLE 97 Malaysia Inflammatory Bowel Disease Treatment Market, 2021 - 2027, USD Million
TABLE 98 Malaysia Inflammatory Bowel Disease Treatment Market by Type, 2017 - 2020, USD Million
TABLE 99 Malaysia Inflammatory Bowel Disease Treatment Market by Type, 2021 - 2027, USD Million
TABLE 100 Malaysia Inflammatory Bowel Disease Treatment Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 101 Malaysia Inflammatory Bowel Disease Treatment Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 102 Malaysia Inflammatory Bowel Disease Treatment Market by Route of Administration, 2017 - 2020, USD Million
TABLE 103 Malaysia Inflammatory Bowel Disease Treatment Market by Route of Administration, 2021 - 2027, USD Million
TABLE 104 Malaysia Inflammatory Bowel Disease Treatment Market by Drug Class, 2017 - 2020, USD Million
TABLE 105 Malaysia Inflammatory Bowel Disease Treatment Market by Drug Class, 2021 - 2027, USD Million
TABLE 106 Rest of Asia Pacific Inflammatory Bowel Disease Treatment Market, 2017 - 2020, USD Million
TABLE 107 Rest of Asia Pacific Inflammatory Bowel Disease Treatment Market, 2021 - 2027, USD Million
TABLE 108 Rest of Asia Pacific Inflammatory Bowel Disease Treatment Market by Type, 2017 - 2020, USD Million
TABLE 109 Rest of Asia Pacific Inflammatory Bowel Disease Treatment Market by Type, 2021 - 2027, USD Million
TABLE 110 Rest of Asia Pacific Inflammatory Bowel Disease Treatment Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 111 Rest of Asia Pacific Inflammatory Bowel Disease Treatment Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 112 Rest of Asia Pacific Inflammatory Bowel Disease Treatment Market by Route of Administration, 2017 - 2020, USD Million
TABLE 113 Rest of Asia Pacific Inflammatory Bowel Disease Treatment Market by Route of Administration, 2021 - 2027, USD Million
TABLE 114 Rest of Asia Pacific Inflammatory Bowel Disease Treatment Market by Drug Class, 2017 - 2020, USD Million
TABLE 115 Rest of Asia Pacific Inflammatory Bowel Disease Treatment Market by Drug Class, 2021 - 2027, USD Million
TABLE 116 Key Information – Allergan PLC
TABLE 117 Key information –Johnson & Johnson
TABLE 118 key Information – Merck Group
TABLE 119 Key Information – Amgen, Inc.
TABLE 120 Key Information – Eli Lilly and Company
TABLE 121 Key Information – Biogen, Inc.
TABLE 122 Key Information – Pfizer, Inc.
TABLE 123 Key Information – Novartis AG
TABLE 124 Key Information – Takeda Pharmaceutical Company Limited
TABLE 125 Key Information – UCB S.A.
List of Figures
FIG 1 Methodology for the research
FIG 2 KBV Cardinal Matrix
FIG 3 Key Leading Strategies: Percentage Distribution (2017-2021)
FIG 4 Key Strategic Move: (Approvals and Trials : 2017, Aug – 2021, Sep) Leading Players
FIG 5 Recent strategies and developments: Merck Group
FIG 6 Recent strategies and developments: Amgen, Inc.
FIG 7 Recent strategies and developments: Biogen, Inc.
FIG 8 Recent strategies and developments: Pfizer, Inc.
FIG 9 Recent strategies and developments: Novartis AG
FIG 10 Recent strategies and developments: Takeda Pharmaceutical Company Limited